Risk-Based Inspections Put Compliant Firms At Risk Of International Snags
This article was originally published in The Tan Sheet
Industry exec asks FDA to help good manufacturers prove to other countries they continue to meet GMPs even if they are not inspected frequently.
You may also be interested in...
President Obama’s FY 2016 blueprint includes cuts to ‘low-priority’ enforcement, surveillance and other activities in FDA human drugs and biologics programs, but still increases those operations overall.
CDER’s Woodcock says the new database will drive risk-based inspection decisions.